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tors. Here, we report that destruxin E (Dx-E), a natural cyclic 
hexadepsipeptide, reduces A  generation without affecting 
BACE or PS/  -secretase activity. In agreement with this, Dx-E 
did not inhibit Notch signaling. We found that Dx-E decreas-
es colocalization of BACE1 and   APP, which reduces   -cleav-
age of   APP. Therefore, the data demonstrate that Dx-E rep-
resents a novel A  -reducing process which could have fewer 
side effects than secretase inhibitors. 
 Copyright © 2009 S. Karger AG, Basel 
 Inhibition of   -amyloid (A  ) generation and en-
hancement of its degradation are proposed as major 
strategies for the treatment of Alzheimer disease  [1, 2] . A 
number of compounds have been developed to inhibit 
  -secretase [i.e.   -amyloid-cleaving enzyme (BACE)] 
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 Abstract 
 Alzheimer-disease-associated   -amyloid (A  ) is produced 
by sequential endoproteolysis of   -amyloid protein precur-
sor (  APP): the extracellular portion is shed by cleavage in 
the juxtamembrane region by   -amyloid-cleaving enzyme 
(BACE)/  -secretase, after which it is cleaved by presenilin 
(PS)/  -secretase near the middle of the transmembrane do-
main. Thus, inhibition of either of the secretases reduces A  
generation and is a fundamental strategy for the develop-
ment of drugs to prevent Alzheimer disease. However, it is 
not clear how small compounds reduce A  production with-
out inhibition of the secretases. Such compounds are ex-
pected to avoid some of the side effects of secretase inhibi-
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and   -secretase [i.e. a complex including presenilin (PS), 
nicastrin, Aph1 and Pen2] enzymes that are involved in 
the generation of A  . Because these compounds are ex-
pected to inhibit the physiological degradation of other 
secretase substrates, they may have side effects  [3–5] . In 
fact, PS1 knockout mice die perinatally and show the 
Notch phenotype due to attenuation of NICD (Notch in-
tracellular cytoplasmic domain) generation from Notch 
receptors  [6, 7] . BACE1 knockout mice also show the pe-
ripheral nerve hypomyelination phenotype caused by 
ablation of neuregulin 1 cleavage  [5] . It is unclear wheth-
er targeting secretases is necessary for inhibiting A  
generation.
 Here, we performed high-throughput screening for 
inhibitors of A  generation and identified destruxin E 
(Dx-E), a natural compound derived from an entomo-
pathogenic fungus. Interestingly, Dx-E reduced   -cleav-
age of   -amyloid protein precursor (  APP) but did not 
inhibit the secretases. The existence of such a compound 
suggests that there is a novel mechanism for inhibiting 
A  generation.
 Materials and Methods 
 Antibodies and Reagents 
 Anti-A  antibodies 6E10 and 4G8 were from Signet Laborato-
ries (Dedham, Mass., USA). The anti-sAPP  Swedish (sw) anti-
body was from IBL (Takasaki, Japan). The anti-BACE1 antibody 
was from Chemicon (Temecula, Calif., USA). The anti-Na + -K + -
ATPase was from Upstate Biotechnology. The anti-calnexin anti-
body was from Stressgen. The anti-early-endosome-antigen 
(EEA) and anti-GM130 antibodies were from BD Transduction 
Laboratories. The   -secretase inhibitors DAPT and L-685,458 
and the BACE inhibitor N-(1S,2R)-1-benzyl-3-(cyclopropylami-
no)-2-hydroxypropyl-5-[methyl(methylsulfonyl)amino-N  -(1R)-
1-phenylethyl]isophthalamide (inhibitor IV) were purchased 
from Calbiochem (San Diego, Calif., USA). The   -secretase 
 substrate NMA-GGVVIATVK(DNP)-DRDRDR-NH 2 was pur-
chased from Calbiochem, and the   -secretase substrate MOCAc-
SEVNLDAEFRK(Dnp)-RR-NH 2 was from Peptide Institute 
(Osaka, Japan). Dx-E was purified by Shionogi and Co. Ltd. In the 
measurement of A  40 and A  42 at a 384-well plate format, the 
addition of compounds and seeding of   APP-overexpressing cells 
were simultaneously performed and incubated for 24 h. In other 
experiments, compounds were mixed in culture medium and lay-
ered onto adherent cells.
 Cell Culture 
 K293 and SH-SY5Y cells stably expressing   APP/PS1/Notch 
derivatives were maintained in DMEM containing 10% FCS and 
antibiotics (200   g/ml G418 for   APP selection, 200   g/ml zeo-
cin for PS1 selection and 100   g/ml hygromycin for Notch1 selec-
tion).
 Measurement of A  Secretion 
 For high-throughput screening, A  40 secretion was measured 
with a homogeneous time-resolved fluorescence kit (Nihon 
Schering, Osaka, Japan) as described in the manufacturer’s in-
structions. Briefly, in a typical 384-well plate assay, 55 ng/ml an-
tibody europium cryptate, 400 ng/ml antibody XL665 and 50 m M 
phosphate buffer (pH 7.4) containing 0.2% BSA and 0.5  M FK were 
added into each well. Samples of conditioned cell culture medium 
or synthetic peptide standards were added to give a total assay 
volume of 20   l/well. The reaction mixture was left at 4 ° C to al-
low equilibrium binding and then read on an ALVO multilabel 
counter (Wallac Oy and Perkin Elmer Inc., Turku, Finland). For 
measurement of A  40 and A  42 in a 96-well plate format, an A  
sandwich enzyme-linked immunosorbent assay (Wako, Japan) 
was used. The cells were incubated for 16 h with compounds. A  
levels were normalized by cell viability as measured using a WST 
system (Nacalai Tesque, Japan).
 Pulse-Chase Experiments 
 Pulse-chase experiments were carried out as previously de-
scribed  [8] .
 Notch Downstream Assays 
 Notch signal reporter assays were carried out as previously 
described  [9] .
 In vitro   -Secretase Assay 
 The peptide substrate for   -secretase (biotin-X-SEVNLDAE-
FRHDSGC) was labeled with europium cryptate (CIS Bio, Mar-
coule, France). Recombinant ectodomain human BACE1 (R & D 
Systems) in reaction buffer (50 m M sodium acetate, pH 5.0, and 
0.008% Triton X-100) with various concentrations of inhibitors 
were mixed with the substrate (18 n M ) in 96-well plates and then 
incubated for 3 h at 30 ° C. Streptavidin-XL665 (0.4   g/well) was 
added, and the reaction was incubated for 1 h at 30 ° C. The homo-
geneous time-resolved fluorescence value [(ratio of fluorescence 
at 665 nm to that at 620 nm)  ! 10,000] in each well was measured 
using an ALVO multilabel counter.
 In vitro   -Secretase Assay 
 Cell-free in vitro   -secretase assays were carried out as previ-
ously described  [10, 11] .
 Cell-Free   -Secretase Assay 
 Following starvation in methionine- and serum-free mini-
mal essential medium for 40 min, the K293 cells stably express-
ing sw   APP were metabolically labeled with 450   Ci of 
[ 35 S]methionine/cysteine (Redivue Promix; Amersham) for 20 
min in methionine- and serum-free minimal essential medium. 
The crude membrane fraction was extracted, and the cell-free 
assay was performed as previously described with a minor change 
 [12] . Briefly, samples of the crude membrane fraction were pre-
incubated with each compound for 1 h and then incubated for 40 
min at 37 ° C (cell-free incubation). The reaction was solubilized 
by the addition of 10 ! radioimmunoprecipitation assay buffer 
(1% sodium dodecyl sulfate, 5% deoxycholate, 10% Triton-X 100) 
and diluted with phosphate-buffered saline containing protease 
inhibitor cocktail. The   APP C-terminal fragments (CTF) pro-
duced during the cell-free reaction were immunoprecipitated 
with antiserum 6618  [12] . Immunoprecipitates were separated on 
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10–20% Tris-tricine gels (Invitrogen, Carlsbad, Calif., USA) and 
analyzed by autoradiography.
 Immunocytochemistry 
 K293 cells stably expressing sw   APP and wild-type (wt) PS1 
were cultured on poly- L -lysine-coated coverslips. Cells were treat-
ed with the reagents at indicated concentrations for 16 h. Cells 
were fixed in 4% paraformaldehyde, permeabilized by 0.1% Tri-
ton-X 100 and blocked with 1% defatted milk, in phosphate-buff-
ered saline. The following primary antibodies were used for im-
munostaining: Monoclonal antibodies for BACE1 and   APP 
(22C11) were from Chemicon. Polyclonal antibody for N-termi-
nal (46–65) BACE1 was from Calbiochem. Polyclonal antibody 
6618 was raised against the C terminus of   APP  [12] . Secondary 
antibodies used were labeled with Alexa 488 or 594 (Invitrogen).
 Subcellular Fractionation 
 Subcellular fractionation was carried out as previously de-
scribed  [12] .
 Results 
 Dx-E Inhibits A  Generation 
 A search for inhibitors of A  generation in a library of 
more than approximately 50,000 compounds by high-
throughput screening identified Dx-E, a cyclodepepsi-
peptide ( fig. 1 A). To confirm the ability of Dx-E to in-
hibit A  generation, we labeled SH-SY5Y cells stably 
 expressing wt   APP by a 30-min pulse with [ 35 S]methio-
nine followed by a 2-hour chase. As shown in  figure 1 B, 
Dx-E (1   M ) decreased the level of secreted A  /p3 species 
(IC 50 approx. 230 n M ;  fig. 1 B, upper panel), although it 
did not significantly change the rate of   APP holoprotein 
degradation ( fig. 1 B, middle and lower panels). We also 
examined whether Dx-E affects the rate of A  degrada-
tion in cell culture. Cells were incubated in conditioned 
medium containing radiolabeled A  and in the absence 
or presence of Dx-E. As shown in  figure 1 C, the rate of 
A  degradation was unchanged by Dx-E treatment. Thus, 
it appears that Dx-E inhibits A  /p3 generation in cell cul-
ture.
 Dx-E Does Not Affect   -Secretase Cleavage of   APP 
 A  generation requires two independent proteolytic 
steps, namely   - and   -cleavages. We first evaluated the 
possibility that Dx-E reduces   -secretase activity. We 
performed an in vitro   -secretase assay  [10] using an in-
tramolecularly quenched fluorogenic peptide probe, 
NMA-GGVVIATVK(DNP)-DRDRDR-NH 2 . This probe 
was mixed with the 1% CHAPSO-soluble membrane 
fraction of cultured cells (containing active PS/  -secre-
tase complex) and incubated for 16 h with Dx-E or 
L685,458, a specific   -secretase inhibitor. As shown in 
 figure 2 A, Dx-E (0.003–10   M ) did not affect   -secretase 
activity in vitro, although L-685,458 inhibited the activ-
ity in a dose-dependent manner. Next, we analyzed 
whether Dx-E inhibits   -cleavage of   APP in living cells 
( fig. 2 B). For the experiments, we used K293 cells stably 
expressing the CTF of   APP (CTF100), a constitutive 
substrate for PS/  -secretase. In contrast to the case of 
full-length   APP, Dx-E did not inhibit A  generation 
from CTF100 ( fig. 2 B). Collectively, these results show 
that the reduction of A  generation by Dx-E is not due to 
inhibition of   -secretase/cleavage.
 Modulators of   -secretase, such as a subset of nonste-
roidal anti-inflammatory drugs, can inhibit A  genera-
tion at relatively higher concentrations than those caus-
ing changes in the relative ratio of A  42 generation  [13] . 
We therefore investigated whether Dx-E is a   -secretase 
modulator. Pulse-chase experiments revealed that Dx-E 
does not change the relative ratio of A  42 species at low-
er concentrations, indicating that it is not a   -secretase 
modulator.
 Dx-E Does Not Affect Notch1 Degradation or Notch 
Signaling 
 The major side effects of   -secretase-inhibiting com-
pounds are due to inhibition of Notch signaling. If Dx-E 
does not affect the activity of PS/  -secretase, it should 
have no influence on Notch signaling. To confirm this, 
we examined whether Dx-E affects Notch signaling in 
cell culture ( fig. 3 A). We used cells stably expressing the 
N1CS construct, a derivative of the Notch1 receptor  [14] . 
The N1CS polypeptide constitutively undergoes sequen-
tial endoproteolysis in the absence of ligand binding  [14] . 
The extent of Notch signaling was determined using a 
luciferase reporter assay in cells expressing  HES-Y  [9] . As 
shown in  figure 3 A, Dx-E treatment did not affect the rate 
of Notch signal transmission, although it dose-depend-
ently reduced A  production. Also, as expected, DAPT, 
a specific   -secretase inhibitor, reduced both A  genera-
tion and Notch signaling ( fig. 3 B). Therefore, Dx-E does 
not perturb Notch signaling even though it inhibits A  /
p3 generation.
 The sequential endoproteolysis of Notch1 consists of 
S2/S3/S4 cleavages. NICD is generated by the S3 cleavage. 
Because Dx-E has distinct effects on the generation of    
and NICD, we examined whether its effects are substrate 
specific. Thus, we analyzed secretion of S2/S4 cleavage-
derived N  , also known as Notch1 A  -like peptides  [8, 
15] ( fig. 3 C). In contrast to specific   -secretase inhibitors, 
Dx-E treatment did not inhibit N  secretion from N1CS-
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expressing cells ( fig. 3 C). Therefore, it appears that Dx-E 
inhibits sequential endoproteolysis of   APP but not of 
Notch1.
 Dx-E Does Not Affect   -Cleavage of   APP in vitro 
 Dx-E reduces A  generation without affecting   -
cleavage of   APP or Notch signaling/cleavage. Therefore, 
we examined whether Dx-E affects   -cleavage of   APP 
by BACE. We examined   -secretase activity in vitro us-
ing an intramolecularly quenched fluorogenic peptide 
probe, MOCAc-SEVNLDAEFRK(Dnp)-RR-NH 2 , and 
recombinant BACE1. Dx-E did not affect BACE1 activity 
at any concentration of Dx-E tested (0.6 n M to 10   M ), 
although the specific BACE inhibitor, inhibitor IV (IC 50 
approx. 20 n M ), affected the activity ( fig. 4 A). We also 
used a newly established cell-free   -secretase assay that 
can detect de novo generation of CTF  from   APP holo-
protein ( fig. 4 B). After a 20-min pulse with [ 35 S]methio-
nine, we extracted the crude membrane fraction from cul-
tured cells and incubated it for 40 min in vitro. Notably, 
addition of Dx-E to the membrane fraction did not de-
crease the generation of CTF  , although inhibitor IV de-
creased the level of CTF  by approximately 70% (p  ! 
0.001 (t test);  fig. 4 B, lower panel). These results indicate 
that Dx-E does not affect BACE activity.
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chase analysis of   APP metabolites was performed in SH-SY5Y 
cells stably expressing wt   APP. Cells were labeled with a 30-min 
pulse of [ 35 S]methionine followed by a 2-hour chase. The condi-
tioned media were collected and immunoprecipitated with anti-
body 4G8 (A  ; upper panel). The   APP holoprotein was immu-
noprecipitated from cell lysate using antiserum 6618  [12] (middle 
panel). Immunoprecipitates were separated by SDS-PAGE and 
analyzed by autoradiography, and the relative decrease in  35 S in-
corporation in   APP holoprotein was analyzed by fluorography 
using a STORM 820 (Amersham). The ratio of   APP holoprotein 
degradation during the 2-hour chase period in untreated cells was 
defined as 100%.  C Effect of Dx-E on degradation of A  in cell 
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hour chase. The medium containing labeled A  was transferred 
to unlabeled cells. The cells were then cultured in the presence or 
absence of Dx-E for 3 h. The labeled conditioned media were col-
lected and immunoprecipitated with 4G8. 
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 Dx-E Inhibits   -Cleavage of   APP in Living Cells 
 We further examined whether Dx-E affects   -cleav-
age by BACE in living cells. K293 ( fig. 4 C) and SH-SY5Y 
( fig. 4 D) cells expressing   APP were pulse labeled for 10 
min and chased for the indicated time. Strikingly, in 
both cell lines, Dx-E drastically decreased secretion of 
soluble   APP  , which is released by   -cleavage of   APP, 
at the same concentration that reduced A  generation 
( fig. 4 C, first panel, and  fig. 4 D, upper panel). In addi-
tion, Dx-E slightly enhanced the secretion of soluble 
  APP  , which is probably a secondary effect due to de-
creased   -cleavage of   APP ( fig. 4 D, lower panel). Dx-E 
affected neither the expression of BACE1 ( fig. 4 C, fourth 
panel) nor the maturation of   APP ( fig. 4 C, second pan-
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el). Therefore, Dx-E decreases   -cleavage of   APP in
living cells.
 Dx-E Decreases Colocalization of   APP and BACE1 
in Cultured Cells 
 Our data that Dx-E decreases   -cleavage of   APP in 
living  cells  without  targeting  to  BACE  enzyme   prompt-
ed us to study a possibility that it affects relative subcel-
lular locations of BACE and   APP. To address this, we 
performed  immunohistochemical  analysis  ( fig.  5 A–J).  
In     untreated     cultured     cells,    immunostaining     with  
 anti-  APP extracellular domain antibody (22C11, red) 
and BACE1 N-terminal domain antibody (Calbiochem 
195101, green) yielded substantial amounts of yellow col-
ors which implies colocalization of the enzyme and the 
substrate ( fig. 5 A, B). However, upon Dx-E treatment, a 
portion of the yellow staining drastically decreased, while 
red/green stainings reciprocally increased ( fig. 5 C, D), 
indicating a marked decrease in the colocalization. In ad-
dition, we compared the distribution of each green or red 
staining with or without Dx-E treatment ( fig. 5 E–G, H–
J), and found that the change of BACE1 distribution 
looked greater than that of   APP.
 To further confirm that Dx-E decreases the colocal-
ization of   APP and BACE1, we performed subcellular 
fractionation of cultured cells and observed the colocal-
ization in each organelle. We immunoblotted each frac-
tion with antibodies to the Na + -K + -ATPase   1 -subunit 
(for plasma membrane marker), EEA1 (for endosome 
marker), calnexin (for endoplasmic reticulum marker) 
and GM130 (for Golgi marker), which confirmed suc-
cessful separation of each organelle ( fig. 6 A, B). Continu-
ously, we tried to observe changes in subcellular distribu-
tion of   APP/BACE1 with or without the treatment of 
Dx-E ( fig. 6 C). Strikingly, the major distribution of 
BACE1 moved from the relatively light fractions (approx. 
fractions 4–7) to heavier fractions (approx. fractions 7–9; 
 fig. 6 C, first and second panels). However, distribution of 
  APP holoprotein and those of the organelle marker pro-
teins did not change so much ( fig. 6 C, third to fourth 
panels, and  fig. 6 A, B). Both the biochemical and immu-
nohistochemical data indicate that Dx-E induces drastic 
A

 s
ec
re
ti
on
 (%
)
0.10.010.001 1 10 100
100
50
0
A
20
40
60
80
100
0
Dx-E (µM)
120
In
h
ib
it
io
n
 o
f
N
ot
ch
 s
ig
n
al
in
g
 (%
)
A

 s
ec
re
ti
on
 (%
)
0.10.010.001 1 10 100
100
50
0
B
20
40
60
80
100
0
DAPT (µM)
120
In
h
ib
it
io
n
 o
f
N
ot
ch
 s
ig
n
al
in
g
 (%
)
C
3.5
6.5
10
15
35S
DM
SO
L6
85
,45
8 (
1µ
M
)
DA
PT
 (1
µM
)
Dx
-E
 (1
µM
)
N21
N25
 Fig. 3. Effects of Dx-E on Notch signaling/cleavage.  A ,  B Notch 
downstream assay. After transient transfection with  HES-Y and 
pRL-TK, cells stably expressing N1CS, sw   APP and wt PS1 were 
treated with Dx-E ( A ) or DAPT ( B ) for 16 h. To analyze Notch sig-
naling, the transcriptional activity of the HES-1 promoter was 
assessed in each condition (red). Conditioned media were col-
lected, and the level of A  was measured (blue).  C N  production 
assay. N1CS-expressing cells were labeled by pulse-chase with 
[ 35 S]methionine. Following treatment with   -secretase inhibitors 
or Dx-E, the N  in conditioned media was analyzed by immuno-
precipitation/autoradiography. Note that N  consists of two dis-
tinct molecular species (N  21 and N  25). 
 Itoh et al. Neurodegenerative Dis 2009;6:230–239236
changes in the subcellular locations of BACE1. Collec-
tively, we suggest that Dx-E induces decreased colocaliza-
tion of matured   APP holoprotein and BACE1 enzyme, 
which may reduce   -cleavage.
 Discussion 
 In this study, we demonstrated that Dx-E reduces A  
generation in a secretase-independent manner. Dx-E in-
hibits   -cleavage of   APP, but it does not affect   - and 
  -secretases. Curiously, colocalization of BACE1 and 
0
20
40
60
80
100
120
Pe
rc
en
t 
of
 c
on
tr
ol
0.001 0.01 0.1
Conc. (µM)
1 10
A
(1 µM)(1 µM)
B
Re
la
ti
ve
 3
5 S
in
co
rp
or
at
io
n
Dx-E BACE inh.
DMSO
*
DMSO
CTF
CTF
0
40
80
120
160
200
240
0 minIncubation 40 min
0 
m
in
30 60 12
0
18
0
24
0
30
0
0 
m
in
30 60 12
0
18
0
24
0
30
0
C
Dx-E (1 µM)
sw APP/HEK293
DMSO
A
sAPP
Mature APP
Immature APP
p3
BACE1 D
Dx-E 
(1 µM)
wt APP/SH-SY5Y
DM
SO
sAPP
sAPP
Chase 0 h 2 h 2 h
 Fig. 4. Effects of Dx-E on   -secretase activity and   -cleavage of 
  APP in cell culture.  A Recombinant BACE1 was mixed with sub-
strates and various concentrations of Dx-E (open circles) or in-
hibitor IV (filled squares).  B The crude membrane fraction from 
[ 35 S]methionine-labeled K293 cells stably expressing sw   APP 
was prepared. The cell-free   -secretase activity was assessed by 
measuring the de novo production of CTF  ; inh. = inhibitor;
 * p  ! 0.001.  C Immunoprecipitation/autoradiography analysis of 
  APP metabolites from K293 cells stably expressing sw   APP and 
wt PS1. After 10 min of metabolic labeling with [ 35 S]methionine, 
the cells were chased at the indicated time points. The condi-
tioned media were collected and immunoprecipitated with 4G8 
(A  ) or anti-sw-sAPP  antibody. The levels of   APP holoprotein 
and BACE1 in the cell lysates were also analyzed.  D Production
of sAPP  and sAPP  by SH-SY5Y cells stably expressing wt 
  APP. 
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 Fig. 5. Effects of Dx-E on the sub-
cellular location of BACE1 and 
  APP. Cells were treated with di-
methylsulfoxide (DMSO,  A ,  B ) or
1   M Dx-E ( C ,  D ) for 16 h. Then, 
  APP ( E ,  H ) and BACE1 ( F ,  I ) were 
immunostained, and cell nuclei 
were counter-stained with diamid-
inophenylindole ( G ,  J ). 
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 Fig. 6. Effects of Dx-E on subcellular lo-
cation of BACE1 and   APP. Fractions 
from a 8.0–25% linear iodixanol gradi-
ent examined by immunoblotting with 
the indicated antibodies. Cells were 
treated with dimethylsulfoxide ( A and 
 C, first and third panels) or 1   M Dx-E 
( B and  C, second and fourth panels) for 
16 h and homogenated followed by sub-
cellular fractionation. 
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  APP was reduced by Dx-E. Our results suggest that Dx-
E represents a novel and advantageous means of reducing 
A  production in Alzheimer disease.
 Dx-E, a member of the destruxin family, is a cyclic 
hexadepsipeptide containing an   -hydroxy acid and 5 
amino acid residues  [16] . This peptide is reported to have 
several biological activities, including inhibition of vacu-
olar-type H + -ATPase, cell cycle arrest and inhibition of 
bone resorption  [16] . The ability of Dx-E to reduce A  
production might be related to these effects. In addition, 
Dx-E is not the only member of the destruxin family that 
can inhibit A  production; we found that destruxin C is 
a weak inhibitor of A  production [Itoh N., unpubl. ob-
servations]. Like Dx-E, bafilomycin and concanamycin 
inhibit the vacuolar-type H + -ATPase and reduce A  se-
cretion from sw-  APP-expressing cells  [17, 18] . However, 
their mechanism of inhibiting   -cleavage is not well un-
derstood.
 To reduce A  generation, inhibitors of either   -cleav-
age or   -cleavage of   APP have been developed. Since 
typical BACE or PS/  -secretase inhibitors inhibit the en-
zymatic activities, they inevitably perturb cleavages of 
substrates other than   APP. Inhibiting the enzymatic 
activities may cause unfavorable side effects because 
these enzymes are deeply involved in neuregulin/Notch 
signaling and play important roles in vivo. Thus, atypical 
compounds have been of note which inhibit A  genera-
tion without disturbing cleavages of other substrates. Es-
pecially, inhibitors that do not affect Notch signaling 
have been sought. For example, Gleevec  is thought to 
target the PS/  -secretase because it inhibits the de novo 
generation of A  in a cell-free assay  [19] . How other com-
pounds such as JLK (nonpeptidic inhibitors of   -secre-
tase), glycogen synthase kinase 3  inhibitors, cerebroly-
sin and berberine inhibit A  generation is unclear  [20–
22] .
 Dx-E, which is neither a BACE nor PS/  -secretase in-
hibitor, can reduce A  generation. Dx-E may decrease A  
by reducing colocalization of   APP and BACE1. The re-
duction of the colocalization is probably induced by dras-
tic changes in the subcellular locations of BACE1. Since 
Dx-E does not change subcellular locations of other pro-
teins such as   APP, Na + -K + -ATPase   1 -subunit, EEA1, 
calnexin and GM130, the effect of Dx-E may be specific 
to BACE1. Dx-E may specifically affect trafficking of 
BACE1. Further study will be needed to elucidate how it 
is achieved. In future, we expect research and develop-
ment of small-molecule inhibitors with processes similar 
to Dx-E.
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